Filing Details

Accession Number:
0001209191-19-059179
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-04 19:47:02
Reporting Period:
2019-12-02
Accepted Time:
2019-12-04 19:47:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346830 Cara Therapeutics Inc. CARA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1166287 T Derek Chalmers C/O Cara Therapeutics, Inc.
4 Stamford Plaza, 107 Elm St, 9Th Floor
Stamford CT 06902
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-02 10,000 $25.79 918,468 No 4 S Direct
Common Stock Acquisiton 2019-12-02 20,000 $0.00 938,468 No 4 A Direct
Common Stock Disposition 2019-12-04 10,699 $17.05 927,769 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.612 to $25.885, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  3. Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
  4. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (3), and does not represent a discretionary trade by the Reporting Person.
  5. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.